Personal information

No personal information available

Activities

Collapse all

Works (4)

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study

Leukemia
2024-11 | Journal article
DOI: 10.1038/s41375-024-02392-7
Contributors: Patrick Derigs; Maria-Luisa Schubert; Peter Dreger; Anita Schmitt; Schayan Yousefian; Simon Haas; Caroline Röthemeier; Brigitte Neuber; Angela Hückelhoven-Krauss; Monika Brüggemann et al.
Source: check_circle
Crossref

Genome editing in clinical practice: A model study for next-gen hematopoietic cell transplants in hematologic malignancies

Molecular Therapy - Methods & Clinical Development
2024-03 | Journal article
DOI: 10.1016/j.omtm.2024.101210
Contributors: Patrick Derigs; Carsten Müller-Tidow
Source: check_circle
Crossref

Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis

Transplantation and Cellular Therapy
2023-12 | Journal article
DOI: 10.1016/j.jtct.2023.09.008
Contributors: Patrick Derigs; Wolfgang A. Bethge; Isabelle Krämer; Udo Holtick; Bastian von Tresckow; Francis Ayuk; Olaf Penack; Vladan Vucinic; Malte von Bonin; Claudia Baldus et al.
Source: check_circle
Crossref

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data

Annals of Hematology
2021-08 | Journal article
DOI: 10.1007/s00277-020-04362-2
Contributors: Patrick Derigs; Aleksandar Radujkovic; Maria-Luisa Schubert; Paul Schnitzler; Tilman Schöning; Carsten Müller-Tidow; Ute Hegenbart; Stefan O. Schönland; Thomas Luft; Peter Dreger et al.
Source: check_circle
Crossref
How many people are using ORCID?